ATAC - Bone Density Sub-Protocol

Study identifier:1033ID/0029

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomised, Double-Blind Trial to Assess the Effects on Bone Mineral Density and Metabolism of Arimidex Alone, Nolvadex Alone, or Arimidex and Nolvadex in Combination, (in Comparison to a Control Group) when used as Adjuvant Treatment for Breast Cancer in Postmenopausal Women

Medical condition

Bone Density

Phase

Phase 3

Healthy volunteers

Study drug

Anastrozole, Tamoxifen

Sex

Female

Actual Enrollment

308

Study type

Interventional

Age

45 Years +

Date

Study Start Date: 01 Jun 1998

Primary Completion Date: 01 Mar 2005

Study Completion Date: 01 Apr 2007

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Other

Verification:

Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Active Comparator: 1 Arimidex 1mg + Nolvadex placebo	Drug: Anastrozole 1mg, orally, once daily Other Name: Arimidex
Active Comparator: 2 Arimidex placebo + Nolvadex 20mg	Drug: Anastrozole 1mg, orally, once daily Other Name: Arimidex Drug: Tamoxifen 20mg, orally, once daily Other Name: Nolvadex
Active Comparator: 3 Arimidex 1mg + Nolvadex 20mg	Drug: Tamoxifen 20mg, orally, once daily Other Name: Nolvadex

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study

800-236-9933

information.center@astrazeneca.com